Choong et al for the ODEX team determine whether polymorphisms within CRTC1 are associated with adiposity markers in psychiatric patients and the general population.
Dombrovski et al describe the neural circuit abnormalities that underlie disadvantageous choices in depressed patients at risk for suicide and relate these abnormalities to impulsivity, which is one of the components of vulnerability to suicide.
Palaniyappan et al determine whether patients with first-episode psychosis who do not respond to 12 weeks of antipsychotic treatment already have significant gyrification defects at illness onset.
Sullivan et al determine whether comorbid depression in patients with type 2 diabetes accelerates cognitive decline.
Goldin et al determine whether cognitive behavioral therapy for social anxiety disorder modifies cognitive reappraisal–related prefrontal cortex neural signal magnitude and timing when implementing cognitive reappraisal with negative self-beliefs.
de la Fuente-Sandoval et al compare glutamate levels in the right associative striatum and right cerebellar cortex using proton magnetic resonance spectroscopy in patients with first-episode psychosis before and 4 weeks after antipsychotic treatment and compare these results with normative data from healthy control subjects.
In a retrospective cohort study, Bobo and coauthors compare the risk of type 2 diabetes in children and youth 6 to 24 years of age for recent initiators of antipsychotic drugs vs propensity score–matched controls who had recently another psychotropic medication.
Hicks et al examine the familial transmission of externalizing disorders among both adoptive (genetically unrelated) and biological relatives to better distinguish genetic and environmental mechanisms of transmission.
Cummings et al examine the availability of outpatient mental health care facilities that accept Medicaid across US counties and whether specific types of communities are more likely to lack this infrastructure.
Khan et al assessed mortality risk among adult patients with a diagnosis of schizophrenia, depression, bipolar disorder, anxiety disorder, or attention-deficit/hyperactivity disorder participating in clinical trials and evaluated if psychopharmacological agents worsen this risk.
Martin and coauthors created 2 new depression measures to explore whether sex disparities in depression rates disappear when alternative symptoms are considered in the place of, or in addition to, more conventional depression symptoms.
In their article, Kahn and Keefe posit that the emphasis on schizophrenia as a psychotic disorder is a conceptual fallacy that has contributed to the lack of progress in understanding this illness and hence has hampered the development of adequate treatments. Stephan Heckers, MD, MSc, provides a related editorial.